SP 0202
Alternative Names: GBP-410; Next Gen PCV - Sanofi; Next-generation pneumococcal conjugate vaccine - Sanofi/SK Bioscience; PCV21; Pneumococcal vaccine conjugate - Sanofi Pasteur/SK Bioscience; SP-0202; SP0202-IIb; SP0202-VI; SP0202-VIILatest Information Update: 26 Dec 2024
Price :
$50 *
At a glance
- Originator sanofi pasteur; SK Chemicals
- Developer Sanofi; Sanofi Pasteur; SK Bioscience; SK Chemicals
- Class Conjugate vaccines; Pneumococcal vaccines; Polysaccharides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Pneumococcal infections
Most Recent Events
- 23 Dec 2024 Phase-III clinical trials in Pneumococcal infections (In infants, In children, In adolescents, Prevention) (unspecified route)
- 18 Dec 2024 Phase-III clinical trials in Pneumococcal infections (In infants, Prevention) in Australia (IM) (NCT06736041)
- 16 Dec 2024 Sanofi plans a phase III trial for in Pneumococcal infections (In infants, Prevention) in Australia (IM) (NCT06736041)